MK-677, also called ibutamoren, is an orally active growth hormone secretagogue. It is a different molecule from sermorelin and works through a different signaling pathway. Calling both growth hormone boosters does not make them interchangeable.
MK-677 research is sometimes used to promote oral sermorelin or a general muscle-building benefit. That leap is not justified: a study of ibutamoren does not establish the absorption, safety, or effectiveness of a sermorelin tablet.
MK-677 trial findings belong to MK-677. They cannot validate another oral product or a sermorelin combination.
What the older-adult trial actually found
A randomized trial in 65 adults aged 60 to 81 examined MK-677 and several outcomes. The investigators reported increased growth hormone and IGF-1 and a change in fat-free mass, but the increase did not translate into improved strength or function in that study.
The trial also found increased fasting glucose and reduced insulin sensitivity. Appetite changes, lower-extremity edema, and muscle pain were among reported effects. These findings are more informative than a headline about lean mass alone. The study's size and functional-outcome limitations also matter when interpreting what it can establish.
Why a scale or scan is not the whole result
Fat-free mass includes more than contractile muscle, and a body-composition change is not identical to lifting more weight, walking farther, or feeling better. Water changes can also complicate the interpretation of weight and appearance.
A meaningful treatment discussion should identify the outcome that matters to the patient and how it will be measured. For older readers, maintaining mobility and day-to-day function may be more useful goals than chasing a hormone number. See muscle-growth evidence for that distinction.
What this tells us about sermorelin
The ibutamoren results show why a pathway response should not be treated as a promise. They do not prove that sermorelin produces the same benefits or the same frequency of adverse effects. Evidence needs to stay attached to the molecule and preparation actually studied.
Likewise, an oral route can be effective for one molecule without validating an oral formulation of another. Read tablets versus injections before assuming that convenient administration establishes reliable delivery or equivalent clinical results.
Compare clinical care, not research-product labels
A research-chemical listing is not a substitute for a patient-specific prescription from a licensed clinician and dispensing pharmacy. A purity claim does not establish clinical suitability, and an online seller's dosing protocol does not provide medical follow-up.
Ask a clinician to evaluate the original concern and discuss established alternatives. If a compounded treatment is proposed, request its exact identity, regulatory context, evidence, and monitoring plan. The pharmacy-check guide explains the verification steps that remain necessary regardless of the product's marketing category.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Nass et al.: MK-677 randomized trial in older adultsPrimary or authoritative reference · Human randomized trial; ibutamoren is not sermorelin.
- Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.
- Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagoguesClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- NABP: Buy medication safelyPharmacy regulator association · Tools for checking online pharmacies and recognizing unsafe sellers.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.